SS-31 10mg

SS-31 (Elamipretide) is a mitochondria-targeting peptide that selectively accumulates within the inner mitochondrial membrane where it binds to and stabilizes cardiolipin—a unique phospholipid essential for optimal mitochondrial structure and function. This targeted mechanism protects cardiolipin from oxidative damage, reduces reactive oxygen species (ROS) production, preserves mitochondrial membrane integrity, and restores efficient energy production in damaged or aging mitochondria. By addressing mitochondrial dysfunction at its source, SS-31 provides comprehensive benefits for cellular energy, cardiovascular health, neuroprotection, and healthy aging.

SS-31 therapy provides comprehensive mitochondrial benefits including enhanced cardiovascular function and exercise tolerance, improved cardiac protection against ischemic injury, significant neuroprotection and cognitive support, dramatically increased cellular energy and reduced fatigue, powerful antioxidant effects and oxidative stress reduction, reversal of age-related mitochondrial decline, improved exercise performance and faster recovery, enhanced metabolic efficiency, reduced inflammation throughout the body, and comprehensive cellular resilience for optimal healthspan. Many patients experience improved energy, mental clarity, physical endurance, and overall vitality.

SS-31 is administered via subcutaneous injection, similar to insulin injections, allowing for convenient self-administration after proper training. The standard therapeutic dose is 10mg administered daily for optimal mitochondrial protection and restoration. Treatment protocols typically run 4-12 weeks depending on individual health goals and therapeutic response, with many individuals benefiting from periodic treatment cycles to maintain optimal mitochondrial function. SS-31 selectively targets mitochondria within hours of administration, with maximal mitochondrial concentration achieved within 24 hours. Your BHRC physician will customize the protocol based on your cardiovascular health, metabolic status, and specific objectives.

Many individuals notice increased energy levels and reduced fatigue within the first 1-2 weeks of SS-31 therapy as mitochondrial function begins to improve. Cardiovascular benefits such as enhanced exercise tolerance and improved endurance typically become apparent within 2-4 weeks of consistent treatment. More significant improvements in cognitive function, metabolic efficiency, recovery capacity, and overall vitality generally develop over 4-8 weeks as cumulative mitochondrial restoration occurs. For comprehensive cardiovascular protection, neuroprotection, and anti-aging benefits, protocols of 8-12 weeks are recommended to allow full mitochondrial regeneration and oxidative stress reduction throughout high-demand tissues.

SS-31 has demonstrated excellent safety in clinical trials with minimal adverse effects due to its highly selective mitochondrial targeting. The most commonly reported side effects are mild and include temporary injection site reactions (redness, mild discomfort) that typically resolve quickly. Rare individuals may experience mild headaches or fatigue during the initial treatment period as cellular metabolism adjusts. SS-31 should be used cautiously in individuals with certain acute cardiac conditions, active malignancies, or specific metabolic disorders. Pregnant or nursing women should avoid SS-31 therapy. Comprehensive cardiovascular evaluation and medical assessment ensure appropriate candidacy and safe protocol implementation.

Yes, SS-31 synergizes exceptionally well with complementary therapies and is frequently incorporated into comprehensive health optimization protocols. SS-31 is often combined with NAD+ therapy for enhanced mitochondrial energy production, peptide therapies targeting muscle growth or recovery (BPC-157, TB-500) for amplified regenerative effects, antioxidant supplementation (glutathione, CoQ10) for comprehensive oxidative stress protection, cardiovascular support therapies, and targeted exercise programs for optimized mitochondrial adaptation. Many patients integrate SS-31 with hormone optimization, metabolic therapies, or longevity interventions for synergistic benefits. Your BHRC physician will design an integrated protocol optimized for your cardiovascular health, performance goals, and therapeutic objectives.

SS-31 therapy is typically not covered by insurance as it’s considered preventive, regenerative, and performance-enhancing medicine focused on mitochondrial optimization and longevity rather than treatment for acute disease. BHRC offers transparent pricing and flexible payment options to make this advanced mitochondrial therapy accessible. Many patients find the investment highly worthwhile given the comprehensive benefits for cardiovascular health, energy, cognitive function, exercise performance, and healthy aging. Some health savings accounts (HSA) or flexible spending accounts (FSA) may cover SS-31 therapy—consult your provider. Our team can provide detailed cost information and discuss payment plans during your consultation.